echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Merck's new COVID-19 drug MK-7110 shows hope for treatment!

    Merck's new COVID-19 drug MK-7110 shows hope for treatment!

    • Last Update: 2021-03-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Merck recently revealed that the FDA would like to see more data on MK-7110 to support its emergency application (EUA) in COVID-19 hospitalized patients.


    FDA COVID-19 immunity

    The interim results of the SAC-COVID study released by OncoImmune in September 2020 show that MK-7110 reduces the risk of death or respiratory failure in hospitalized patients with moderate to severe COVID-19 by more than 50%.


    MK-7110 reduces the risk of death or respiratory failure in hospitalized patients with moderate to severe COVID-19 by more than 50%.


    Earlier this year, Merck said it would focus on MK-7110 and MK-4482.


     

    Original source:

    Original source:

    https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.